Asked by: Tracey Crouch (Conservative - Chatham and Aylesford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of (a) the Voluntary Scheme for Branded Medicines Pricing and Access and (b) the introduction of the severity modifier on decisions of companies to launch medicines in the UK.
Answered by Will Quince
The National Institute for Health and Care Excellence (NICE) is able to recommend the vast majority of cancer medicines it appraises and its approval rate for cancer medicines has consistently been around 90%. NICE concluded a comprehensive review of its methods in January 2022 and has introduced a number of changes that will make its processes fairer and faster, and ensure they provide more equitable access for those with severe diseases. This includes a broader severity modifier to replace the end of life modifier. Analysis carried out by NICE in the development of the modifier indicates that the vast majority of cancer medicines that would be eligible for the end of life modifier would also be eligible for a weighting under the severity modifier. NICE recently reviewed the topics appraised using its new methods and found that of the seven pieces of final guidance published up until December 2022, all seven make positive recommendations. NICE also found that the severity modifier supported a positive recommendation where it was accepted, and plans to further review the implementation of its methods towards the end of 2023.
New innovative medicines do not pay the voluntary scheme for branded medicines pricing and access (VPAS) rebate rate for the first three years after marketing authorisation. The National Health Service is a unique proposition for global life sciences companies. With a single commercial deal, a company can have access to a market of over 55 million people. A recent report from the Pharmaceutical Research and Manufacturers of America found that between 2012 and 2021, the United Kingdom was consistently in the top three G20 countries for availability and speed of access to new medicines.
Asked by: Tracey Crouch (Conservative - Chatham and Aylesford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will monitor the impact of the severity modifier on access to new end of life cancer medicines.
Answered by Will Quince
The National Institute for Health and Care Excellence (NICE) is able to recommend the vast majority of cancer medicines it appraises and its approval rate for cancer medicines has consistently been around 90%. NICE concluded a comprehensive review of its methods in January 2022 and has introduced a number of changes that will make its processes fairer and faster, and ensure they provide more equitable access for those with severe diseases. This includes a broader severity modifier to replace the end of life modifier. Analysis carried out by NICE in the development of the modifier indicates that the vast majority of cancer medicines that would be eligible for the end of life modifier would also be eligible for a weighting under the severity modifier. NICE recently reviewed the topics appraised using its new methods and found that of the seven pieces of final guidance published up until December 2022, all seven make positive recommendations. NICE also found that the severity modifier supported a positive recommendation where it was accepted, and plans to further review the implementation of its methods towards the end of 2023.
New innovative medicines do not pay the voluntary scheme for branded medicines pricing and access (VPAS) rebate rate for the first three years after marketing authorisation. The National Health Service is a unique proposition for global life sciences companies. With a single commercial deal, a company can have access to a market of over 55 million people. A recent report from the Pharmaceutical Research and Manufacturers of America found that between 2012 and 2021, the United Kingdom was consistently in the top three G20 countries for availability and speed of access to new medicines.
Asked by: Tracey Crouch (Conservative - Chatham and Aylesford)
Question to the Home Office:
To ask the Secretary of State for the Home Department, when she plans to bring forward legislation making it a criminal offence to be in possession of NOS canisters.
Answered by Chris Philp - Shadow Leader of the House of Commons
The Government has committed to control nitrous oxide as a Class C drug before the end of the year.
We will bring forward legislation as soon as possible, but this will remain subject to Parliamentary procedure.
Asked by: Tracey Crouch (Conservative - Chatham and Aylesford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce waiting times for (a) endoscopies and (b) other bowel cancer diagnostic tests.
Answered by Helen Whately - Shadow Secretary of State for Transport
£2.3 billion was awarded at Spending Review 21 to transform diagnostic services over the next three years. Most of this will help increase the number of Community Diagnostic Centres (CDCs) up to 160 by March 2025, expanding and protecting elective planned diagnostic services, including a number delivering endoscopy services. The remainder will increase diagnostic capacity, including endoscopy services, and other productivity improvements including digital transformation.
Direct Spending Review 21 investment in Endoscopy capacity has resulted in a net additional 31 endoscopy rooms in 2022/23, of which five were in CDCs. To date, NHS England have also approved additional investment, expected to deliver a further 25 net endoscopy rooms, of which five are to be in CDCs.
Alongside investment in physical capacity, several schemes are already underway to grow the endoscopy workforce including international recruitment of Clinical Fellows to enable back-fill for gastroenterology trainees to complete training.
Asked by: Tracey Crouch (Conservative - Chatham and Aylesford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to reduce the FIT screening for bowel cancer threshold from 120 ug/g to 20ug/g.
Answered by Will Quince
The Department and NHS England are working together to look at reducing the FIT screening threshold for Bowel cancer, including calculating the workforce capacity that would be needed.
Asked by: Tracey Crouch (Conservative - Chatham and Aylesford)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, what progress she has made in negotiations with the European Commission on awarding Great Britain Part 1 listed status to enable pet owners to travel outside the UK with fewer restrictions.
Answered by Trudy Harrison
We are continuing to engage with the European Commission on awarding Great Britain 'Part 1' listed status and recognition of the UK's tapeworm-free status.
Asked by: Tracey Crouch (Conservative - Chatham and Aylesford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what proportion of NICE appraisals have been terminated in (a) 2018-2019, (b) 2019-2020, (c) 2020-2021 and (d) 2021-2022.
Answered by Will Quince
The following table shows the number of appraisals terminated by the National institute for Health and Care Excellence (NICE) for the timeframes requested:
| 2018/19 | 2019/20 | 2020/21 | 2021/22 |
Appraisals published (including terminated appraisals) | 56 | 53 | 63 | 94 |
Terminated appraisals | 6 | 10 | 13 | 19 |
Appraisals were terminated due to the company not making an evidence submission to NICE. NICE requires companies to submit evidence on the technology or technologies being evaluated. In line with its established process and methods, NICE terminates an evaluation if no evidence submission is received.
Asked by: Tracey Crouch (Conservative - Chatham and Aylesford)
Question to the Department for Education:
To ask the Secretary of State for Education, how many parents of deaf children participated in British sign language courses that were funded through the adult education budget in Kent and Medway in each of the last three years.
Answered by Claire Coutinho - Shadow Secretary of State for Energy Security and Net Zero
The department is continuing to invest in education and skills training for adults through the Adult Education Budget (AEB), which was £1.34 billion in the 2022/23 financial year.
This includes qualifications in, or focusing on, British Sign Language (BSL) up to and including level 2. These qualifications include, for example, the Level 1 Award in BSL which allows learners to communicate in BSL on a range of topics that involve simple, everyday language use, thereby giving them the basic skills and confidence in production and reception of BSL.
About 60% of the AEB has been devolved to Mayoral Combined Authorities and the Greater London Authority, who determine which provision to fund for learners who live in their areas. The Education and Skills Funding Agency provides the remaining funding for learners who live in non-devolved areas. Where community learning providers offer BSL courses, those providers are responsible for determining the course fees, including levels of fee remission.
There were 60 adult (19+) education and training learning aim enrolments in the 2021/22 academic year by learners living in Kent or Medway with ‘British Sign Language’ or ‘BSL’ in their aim title. In 2020/21, there were 35 enrolments and in 2019/20, there were 87. The department does not hold information as to whether the learners taking these aims have deaf children.
These figures do not correspond to learners, as learners may enrol on multiple aims. Additionally, these are funded adult (19+) education and training aim enrolments. This will include AEB-funded learning, as well as other funding provision, such as advanced learner loans.
Asked by: Tracey Crouch (Conservative - Chatham and Aylesford)
Question to the Ministry of Housing, Communities and Local Government:
To ask the Secretary of State for Levelling Up, Housing and Communities, when his Department plans to publish the Strategy for Community Spaces and Relationships.
Answered by Dehenna Davison
We want to consult and work with local communities and stakeholders to understand how community spaces and relationship could be strengthened. This work will begin in due course.
Asked by: Tracey Crouch (Conservative - Chatham and Aylesford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what his Department's estimated timescale is for bringing into force the removal of the financial burden for In-Vitro Fertilisation for female same-sex couples in England.
Answered by Maria Caulfield
Funding decisions for health services in England, including In-Vitro Fertilisation (IVF), are made by integrated care boards (ICBs) and are based on the clinical needs of their local population. We expect the removal of the additional financial burden faced by female same-sex couples when accessing IVF treatment to take effect during 2023.